

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

Claims 1-16 (canceled)


**Claim 17 (currently amended):** A compound of formula 1:



wherein  $\text{Ar}^1$  is



wherein  $\text{R}^{12}$  is selected from the group consisting of



$\text{R}^{13}$  represents Cl, Br,  $\text{COO}(\text{C}_{1-4})\text{alkyl}$  and  
if  $\text{R}^9$  is  $\text{NO}_2$ , Cl or Br, then  $\text{R}^{13}$  may also represent F or  $\text{CH}_3$ ;

$\text{R}^{14}$ ,  $\text{R}^{15}$ ,  
 $\text{R}^{31}$ ,  $\text{R}^{32}$ ,


**R<sup>33</sup>** are each independently selected from the group consisting of H, (C<sub>1-6</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl-(C<sub>1-3</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, O-(C<sub>1-4</sub>)alkyl, S-(C<sub>1-4</sub>)alkyl, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OH, NO<sub>2</sub>, CN, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>-(C<sub>1-4</sub>)alkyl, C(O)OR<sup>1</sup> wherein **R<sup>1</sup>** is H or (C<sub>1-4</sub>)alkyl, or NR<sup>2</sup>R<sup>3</sup> wherein **R<sup>2</sup>** and **R<sup>3</sup>** each independently is H or (C<sub>1-4</sub>)alkyl;

**R<sup>30</sup>** represents H, Cl, Br, COO(C<sub>1-4</sub>)alkyl; and

**X** is S or O;

**W** is CH<sub>2</sub>C(O)NR<sup>6</sup> wherein **R<sup>6</sup>** is H or (C<sub>1-4</sub>)alkyl; and

**Ar<sup>2</sup>** is selected from the group consisting of




wherein **R<sup>9</sup>** is halo or NO<sub>2</sub>; and if **R<sup>13</sup>** is Cl or Br, then **R<sup>9</sup>** may also represent (C<sub>1-3</sub>)alkyl;

**R<sup>10</sup>**, **R<sup>11</sup>** are independently of each other selected from the group consisting of H, (C<sub>1-6</sub>)alkyl, (C<sub>3-7</sub>)Cycloalkyl, (C<sub>3-7</sub>)Cycloalkyl-(C<sub>1-3</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, O(C<sub>1-6</sub>)alkyl, S(C<sub>1-6</sub>)alkyl, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OH, NO<sub>2</sub>, CN, -NR<sup>N1</sup>R<sup>N2</sup>, -C(O)R<sup>21</sup>, -(C<sub>1-3</sub>)alkyl-C(O)R<sup>21</sup>, -C(O)OR<sup>22</sup>, -(C<sub>1-3</sub>)alkyl-C(O)OR<sup>22</sup>, -SO<sub>2</sub>-(C<sub>1-3</sub>)alkyl-C(O)OR<sup>22</sup>, wherein **R<sup>21</sup>** is (C<sub>1-4</sub>)alkyl and **R<sup>22</sup>** is H or (C<sub>1-4</sub>)alkyl; -(C<sub>1-3</sub>)alkyl-C(O)NH<sub>2</sub>, C(O)NH<sub>2</sub>, S(O)-(C<sub>1-6</sub>)alkyl, -SO<sub>2</sub>-(C<sub>1-6</sub>)alkyl, -SO<sub>2</sub>-phenyl, -SO<sub>2</sub>-NH<sub>2</sub>, phenyl, phenylmethyl, 2-, 3- or 4-pyridinyl, 1-pyrrolyl, whereby said phenyl, pyridinyl and pyrrolyl may have one or more substituents selected from the group consisting of halo, NO<sub>2</sub>, C<sub>1-3</sub>-alkyl and CF<sub>3</sub>;


wherein **R<sup>N1</sup>**, **R<sup>N2</sup>** each independently represent H or (C<sub>1-6</sub>)alkyl, whereby **R<sup>N1</sup>** and **R<sup>N2</sup>** may be covalently bonded to each other to form together with the N-atom to which they are attached to a 4 to 7-membered heterocycle whereby the -CH<sub>2</sub>- group at the position 4 of a 6 or 7-membered heterocycle may be replaced by -O-, -S- or -NR<sup>N3</sup>- wherein **R<sup>N3</sup>** represents H, -C(O)OR<sup>22</sup>, (C<sub>1-6</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl or (C<sub>3-7</sub>)cycloalkyl-(C<sub>1-3</sub>)alkyl, wherein **R<sup>22</sup>** is H or (C<sub>1-4</sub>)alkyl;

or a pharmaceutically acceptable salt thereof.

**Claim 18 (previously presented):** The compound of formula 1 according to claim 17 wherein **Ar**<sup>1</sup> is



wherein **R**<sup>12</sup> is selected from the group consisting of



wherein **R**<sup>13</sup>, **R**<sup>14</sup>, **R**<sup>15</sup>, **R**<sup>30</sup>, **R**<sup>31</sup>, **R**<sup>32</sup> and **R**<sup>33</sup> are as defined in claim 17.

**Claim 19 (original):** The compound of formula 1 according to claim 18 wherein

**R**<sup>13</sup> represents Cl or Br and

if **R**<sup>9</sup> is NO<sub>2</sub>, Cl or Br, then **R**<sup>13</sup> may also represent F or CH<sub>3</sub>;


**R**<sup>14</sup>, **R**<sup>15</sup>,

**R**<sup>31</sup>, **R**<sup>32</sup>,


**R**<sup>33</sup> are each independently selected from the group consisting of H, (C<sub>1-6</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl-(C<sub>1-3</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, O-(C<sub>1-4</sub>)alkyl, S-(C<sub>1-4</sub>)alkyl, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OH, NO<sub>2</sub>, CN, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>-(C<sub>1-4</sub>)alkyl, C(O)OR<sup>1</sup> wherein **R**<sup>1</sup> is H or (C<sub>1-4</sub>)alkyl, or NR<sup>2</sup>R<sup>3</sup> wherein **R**<sup>2</sup> and **R**<sup>3</sup> each independently is H or (C<sub>1-4</sub>)alkyl; and **R**<sup>30</sup> represents Cl or Br.

**Claim 20 (original):** The compound of formula 1 according to claim 19 wherein **W** is CH<sub>2</sub>C(O)NH.

**Claim 21 (original):** A compound according to claim 17 wherein




wherein **R**<sup>12</sup> is selected from the group consisting of



**X** is S;


**W** is  $\text{CH}_2\text{C(O)NR}^6$  wherein  $\text{R}^6$  is H or  $(\text{C}_{1-4})$ alkyl; and

**Ar<sup>2</sup>** is




wherein  $\text{R}^9$  is halo or  $\text{NO}_2$ ; or

**Ar<sup>2</sup>** is



wherein  $\text{R}^9$  is halo or  $\text{NO}_2$  and  $\text{R}^{10}$  is halo; or


**Ar<sup>2</sup>** is




wherein  $\text{R}^9$  is halo or  $\text{NO}_2$ , and  $\text{R}^{10}$  is OMe, halo, OH,  $\text{NO}_2$ , phenyl,  $\text{C(O)OH}$  or  $\text{C(O)OMe}$ .

**Claim 22 (canceled)**


**Claim 23 (original):** A compound of formula 1, according to claim 17, wherein **Ar**<sup>1</sup> is:



and wherein **R**<sup>12</sup> selected from the group consisting of:




And



**Claim 24 (canceled)**

**Claim 25 (currently amended):** A compound of formula 1, according to claim 17, wherein

**Ar<sup>2</sup>** is selected from the group consisting of



wherein **R<sup>9</sup>** is Cl or NO<sub>2</sub> and


**R<sup>10A</sup>** is C<sub>1-4</sub>alkyl;


**R<sup>10</sup>** is selected from the group consisting of (C<sub>1-4</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl-(C<sub>1-3</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, O(C<sub>1-6</sub>)alkyl, S(C<sub>1-6</sub>)alkyl, halo, CF<sub>3</sub>, OCF<sub>3</sub>, OH, NO<sub>2</sub>, CN, -NR<sup>N1</sup>R<sup>N2</sup>, -C(O)R<sup>21</sup>, -(C<sub>1-3</sub>)alkyl-C(O)R<sup>21</sup>, -C(O)OR<sup>22</sup>, -(C<sub>1-3</sub>)alkyl-C(O)OR<sup>22</sup>, -SO<sub>2</sub>-(C<sub>1-3</sub>)alkyl-C(O)OR<sup>22</sup>, -(C<sub>1-3</sub>)alkyl-C(O)NH<sub>2</sub>, C(O)NH<sub>2</sub>, -S(O)-(C<sub>1-6</sub>)alkyl, -SO<sub>2</sub>-(C<sub>1-6</sub>)alkyl, -SO<sub>2</sub>-phenyl, -SO<sub>2</sub>-NH<sub>2</sub>, phenyl, phenylmethyl, phenyl-SO<sub>2</sub>-, 2-, 3- or 4-pyridinyl, 1-pyrrolyl, whereby said phenyl, pyridinyl and pyrrolyl may have one or more substituents selected from the group consisting of halo, NO<sub>2</sub>, C<sub>1-3</sub>-alkyl and CF<sub>3</sub>;

wherein **R<sup>21</sup>** is (C<sub>1-4</sub>)alkyl and **R<sup>22</sup>** is H or (C<sub>1-4</sub>)alkyl;

wherein **R<sup>N1</sup>**, **R<sup>N2</sup>** each independently represent H or (C<sub>1-6</sub>)alkyl, whereby **R<sup>N1</sup>** and **R<sup>N2</sup>** may be covalently bonded to each other to form together with the N-atom to which they are attached to a 4 to 7-membered heterocycle whereby the -CH<sub>2</sub>-group at the position 4 of a 6 or 7-membered heterocycle may be replaced by -O-, -S- or -NR<sup>N3</sup>- wherein **R<sup>N3</sup>** represents H, -C(O)OR<sup>22</sup>, (C<sub>1-6</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl or (C<sub>3-7</sub>)cycloalkyl-(C<sub>1-3</sub>)alkyl, wherein **R<sup>22</sup>** is H or (C<sub>1-4</sub>)alkyl.

**Claim 26 (original):** A compound of formula 1, according to claim 25, wherein **Ar<sup>2</sup>** is:





**Claim 27 (canceled)**

**Claim 28 (original):** A pharmaceutical composition comprising a compound of formula **1** as defined in claim 17, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carriers.

**Claim 29 (canceled)**

**Claim 30 (original):** A pharmaceutical composition for the treatment of HIV infection, comprising a compound of formula **1** as defined in claim 17, or a pharmaceutically acceptable salt thereof.

**Claim 31 (canceled)**